Download the app
App StorePlay Store
Beige
Login
← All tags

health policy

Eli Lilly pauses India obesity campaign after regulator warning and seeks clearer promotion rules

Eli Lilly pauses India obesity campaign after regulator warning and seeks clearer promotion rules

Eli Lilly has paused its obesity awareness campaign in India after the country’s drug regulator cautioned it over potential rule violations. The initiative sought to reframe obesity as a chronic disease using multiple media formats without naming specific products. Lilly says regulatory uncertainty and conflicting guidance led to the halt, while the regulator warned against indirect promotion of medicines.

Summarised by Beize from a story on The Economic Times on 12 May 2026
White House moves to fire FDA chief Marty Makary as acting commissioner choice emerges

White House moves to fire FDA chief Marty Makary as acting commissioner choice emerges

The White House has reportedly signed off on a plan to fire U.S. FDA Commissioner Marty Makary, signaling a potential leadership shake-up at the federal health agency. Sources say the White House is considering naming FDA Deputy Commissioner Kyle Diamantas, who oversees the agency’s food division, as acting commissioner. The move follows heightened fallout tied to controversial drug, abortion, and vape issues.

Summarised by Beize from a story on Republic on 9 May 2026

Your news, in seconds

App StorePlay Store
India ramps up drug regulator overhaul with recruitment of 1500 scientists and tech specialists

India ramps up drug regulator overhaul with recruitment of 1500 scientists and tech specialists

India’s drug regulator is starting a major overhaul by planning to recruit more than 1,500 scientists and technology specialists. The move is designed to streamline drug approval processes and bring them closer to international benchmarks. Officials say the expanded expertise will strengthen pharmaceutical governance and help the regulator work faster and more consistently as the sector evolves.

Summarised by Beize from a story on The Economic Times on 5 May 2026
Trump drugmaker deals could cut US costs by 529 billion over a decade White House claims

Trump drugmaker deals could cut US costs by 529 billion over a decade White House claims

The White House says President Trump’s deals with drugmakers could save the US economy $529 billion over 10 years by bringing prescription prices down toward levels seen in other developed countries. The effort is set to be a major talking point ahead of midterm elections, even as Democrats question whether the projected savings will hold up.

Summarised by Beize from a story on The Economic Times on 5 May 2026
ICMR chief urges India to build its own rare disease treatment playbook

ICMR chief urges India to build its own rare disease treatment playbook

ICMR’s chief says India should chart its own path for rare disease treatment instead of relying on conventional Western approaches. The focus is on local innovation and smarter use of limited resources to create care strategies tailored to India’s realities. The shift signals a move toward indigenous solutions and more efficient, context-specific healthcare planning for patients with rare conditions.

Summarised by Beize from a story on The Economic Times on 5 May 2026
Patients voice enters drug pricing reform committee expanding for faster fairer outcomes

Patients voice enters drug pricing reform committee expanding for faster fairer outcomes

A key committee reviewing India’s drug pricing reforms has been expanded to include patients, shifting the debate from numbers on paper to real healthcare impact. The move aims to make pricing decisions more grounded in affordability and access, potentially influencing how reforms are designed and implemented as stakeholders push for faster, fairer outcomes.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026

Never miss a story

App StorePlay Store
India Digital Health Framework Shows Real Scale but Still Lacks Full Scope

India Digital Health Framework Shows Real Scale but Still Lacks Full Scope

India’s digital health push is building on proven playbooks like UPI and CoWIN, demonstrating the country can deploy population-level systems at speed. However, the framework’s scope is still evolving, leaving open questions about how broadly it will cover, what data will be used, and how smoothly services will integrate across the health ecosystem.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Page 1

The full experience is on mobile.

Swipe through stories, personalise your feed, and save articles for later — all on the app.

Download on the App StoreGet it on Google Play